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Abstract
Introduction: COPD exacerbation is a life-threatening condition with acute dyspnoea caused by respiratory or circulatory distress. 
The significance and co-presence of lung hyperinflation, bronchial obstruction, and changes in haemodynamics in the course of 
COPD exacerbation treatment have not been well described yet in course of a single study.
Our aim was to evaluate the influence of COPD exacerbation treatment on bronchial obstruction, pulmonary hyperinflation, and 
possible changes of right and left ventricle haemodynamics in relation to the patient’s clinical status. 
Material and methods: A total of 40 patients (90% males), 67 ± 8 years old, with COPD were assessed pre- and post-exacer-
bation treatment by the following: respiratory function tests, transthoracic echocardiography, 6MWT, endothelin-1 (ET-1) and 
NT-proBNP serum concentrations, and MRC scale. 
Results: A significant decrease in RV%TLC (%) and mean pulmonary artery pressure (PAPmean) [mm Hg] was observed: pre
-RV%TLC: 64.3 ± 9.0; post-RV%TLC 60.6 ± 11.1; p = 0.03; pre-PAPmean: 41.2 ± 11.2; post-PAPmean: 39.1 ± 12.1; p = 0.029, 
coupled with a significant increase of FEV1 [L]-preFEV1: 1.0 ± 0.4, post-FEV1: 1.2 ± 0.5; p < 0.001. A trend for reduced right ven-
tricle systolic pressure (RVSP) [mm Hg]: pre-treatment: 44.5 ± 12.9; post-treatment: 36.3 ± 14.3; p = 0.068 and ET-1 [fmol/ml]: 
pre-treatment: 1.7 ± 2.8; post-treatment: 1.3 ± 1.9; p = 0.076, but not for NT-proBNP was noticed. Improvement of both, 6MWT 
[m]: pre-treatment: 294 ± 132; post-treatment: 415 ± 102; p < 0.001 and MRC [pts.]: pre-treatment: 3.3 ± 0.8; post-treatment: 
1.8 ± 0.9; p < 0.001, were noticed. 6MWT correlated with RV%TLC (p < 0.05; r = –0.46; r = –0.53; respectively) and FEV1 (p < 
0.05; r = 0.55; r = 0.60, respectively) on admission as well as on discharge. There was no such correlation with RVSP or PAPmean. 
Conclusions: Pulmonary hyperinflation and bronchial obstruction may be reduced by effective COPD exacerbation treatment and 
are accompanied by clinical improvement. 
The mPAP reduction observed in the course of treatment was not correlated with the results of 6MWT and MRC score.
Key words: COPD exacerbation, dyspnoea, pulmonary hyperinflation, pulmonary hypertension, bronchial obstruction, 6-minute 
walk test
Pneumonol. Alergol. Pol. 2015; 83: 30–38
Streszczenie
Wstęp: Zaostrzenie POChP jest stanem zagrożenia życia, któremu towarzyszy duszność wtórna do przeciążenia układów od-
dechowego i/lub krążenia. Jak dotąd w pojedynczym badaniu nie określono istotności klinicznej zmian hiperinflacji, obturacji 
i wydolności układu krążenia w przebiegu leczenia zaostrzenia POChP. 
Celem badania była ocena wpływu leczenia zaostrzenia POChP na nasilenie obturacji oskrzeli, rozdęcia płuc, oraz na zmianę stanu 
hemodynamicznego chorych leczonych z powodu zaostrzenia POChP. 
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Materiał i metody: Do badania włączono 40 pacjentów w wieku 67 ± 8 lat (90% mężczyzn) hospitalizowanych z powodu zaostrzenia 
POChP. Chorych badano przed i po zakończeniu leczenia z zastosowaniem: badań czynnościowych układu oddechowego, echokardio-
grafii przezklatkowej, sześciominutowego testu marszowego, stężeń Endoteliny-1 i NT-proBNP w surowicy krwi oraz skali mMRC. 
Wyniki: W trakcie leczenia zaobserwowano istotne zmniejszenie rozdęcia płuc: przed-RV%TLC: 64,3 ± 9,0; po-RV%TLC 60,6 ± 
11,1; p = 0,03;, zmniejszenie obturacji FEV1[L] przed FEV1: 1,0 ± 0,4, po-FEV1: 1,2 ± 0,5; p < 0,001; oraz obniżenie średniego 
ciśnienia w tętnicy płucnej (PAPmean) [mm Hg]: przed-PAPmean: 41,2 ± 11,2; po-PAPmean: 39,1 ± 12,1; p = 0,029. Zaob-
serwowano trend do zmniejszenia skurczowego ciśnienia w prawej komorze serca (RVSP) [mm Hg]: przed-RVSP: 44,5 ± 12,9; 
po-RVSP: 36,3 ± 14,3; p = 0,068 oraz stężenia ET-1 [fmol/ml]: przed- ET-1: 1,7 ± 2,8; po-ET-1: 1,3 ± 1,9; p = 0,076, lecz nie 
NT-proBNP. Zaobserwowano wydłużenie dystansu 6MWT: przed: 294 ± 132; po-leczeniu: 415 ± 102; p < 0.001; oraz zmniej-
szenie duszności: przed-MRC: 3,3 ± 0,8; po-MRC: 1,8 ± 0,9; [pkt.] p < 0,001. Dystans 6MWT i wynik testu MRC korelowały 
z RV%TLC (p < 0,05; odpowiednio r = –0,58; r = 0,51), lecz nie z RVSP czy PAPmean.
Wnioski: W trakcie leczenia zaostrzenia POChP obserwuje się zmniejszenie rozdęcia płuc i obturacji oskrzeli. Koreluje to ze 
zmniejszeniem duszności i poprawą wydolności wysiłkowej. Zaobserwowane w trakcie leczenia obniżenie mPAP nie koreluje 
z wydłużeniem dystansu 6MWT czy nasileniem duszności mierzonym za pomocą skali mMRC. 
Słowa kluczowe: zaostrzenie POChP, duszność, rozdęcie płuc, nadciśnienie płucne, obturacja oskrzeli, 6 minutowy test marszowy 
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Introduction
Chronic obstructive pulmonary disease 
(COPD) is one of the leading causes of mortality 
worldwide [1]. In most subjects, symptoms and 
mortality are respiratory and/or cardiovascular 
dependent. More over, dynamic hyperinflation in 
COPD is associated with poor cardiovascular re-
sponse to exercise [2]. COPD acute exacerbations 
are determined not only by lung function impair-
ment but also frequently by cardiovascular dete-
rioration [3]. That is why simultaneous analysis 
of both systems should be performed when asses-
sing patients with COPD exacerbation. Although 
COPD staging is based on FEV1 [4], it has been 
accepted that lung hyperinflation has a greater 
impact on dyspnoea and exercise intolerance than 
does decrease of FEV1 [5]. Static hyperinflation is 
caused by distal airway collapsing on exhalation 
and subsequent air trapping. It can result in an 
increase in the RV%TLC ratio, if total lung capa-
city (TLC) exceeds normal values. In patients with 
COPD, during exercise, dynamic hyperinflation 
not only increases expiratory flow limitation, but 
also has haemodynamic consequences resulting 
from more rapid, shallow breathing and pro-
gressive reduction in dynamic lung compliance. 
That explains both exercise intolerance and gas 
exchange disturbances [6]. Dynamic hyperinfla-
tion is not present in all COPD patients [7, 8]. 
It appears when oxygen demand increases. In 
most severe COPD stages hyperinflation may 
develop on mild exercise [9], and this results in 
inspiratory capacity (IC) decline and dyspnoea.
Pulmonary hypertension (PHT), defined as 
mean pulmonary artery pressure (PAPmean) ≥ 25 mm 
Hg, is considered as a frequent and serious COPD 
complication [10]. Pulmonary artery pressure (PAP) 
may increase with COPD exacerbation and it has 
a predictive value for decreased survival [11]. Accor-
ding to the European Respiratory Society/European 
Society of Cardiology (ERS/ESC guidelines) [10], 
PHT in COPD patients might not only be secon-
dary to hypoxaemia, but also to left heart disease. 
Concentration of NT-proBNP is an independent 
predictor of poor prognosis in patients treated for 
heart failure [12], but may also have some predic-
tive value in COPD exacerbation [13]. It has been 
proven that endothelin-1 (ET-1) concentration is 
increased in COPD patients, but its levels are not 
PHT-dependent [14]. ET-1 levels also increase in 
the course of COPD exacerbation, but no correla-
tion with the severity of PHT has been found [15]. 
The purpose of this study was to examine 
the relationship between exercise capacity and 
dyspnoea with respiratory function parameters, 
echocardiographic indexes of cardiac function, 
and trends of serum markers related to cardiac 
decompensation in patients undergoing COPD 
exacerbation treatment.
Material and methods 
The study complied with the principles of 
the Declaration of Helsinki. The protocol was 
approved by the Ethics Committee of the Me-
dical University. All patients gave their written 
informed consent.
Study population 
Forty-three patients were screened. Those 
with COPD exacerbation definition according 
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to the Global Initiative for Chronic Obstructi-
ve Lung Disease (GOLD) [4], who met all inc-
lusion criteria and were free of exclusion criteria 
(40 patients 67 ± 8 years, 90% males), took part 
in the study and were admitted to the Pulmo-
nology Department. Inclusion criteria were as 
follows: 1) COPD exacerbation with indications 
for hospitalization (GOLD, Anthonisen- criteria) 
[4, 16], 2) age > 40 years, and 3) smoking status 
≥ 20 pack-years, LVEF within normal values, and 
no valvular heart diseases. 
Exclusion criteria were as follows: 1) chronic/ 
/acute pulmonary disease other than COPD, 2) PHT 
other than secondary to COPD, diagnosed with the 
use of the European Society of Cardiology guideli-
nes for the diagnosis and treatment of pulmonary 
hypertension [10], 3) hereditary AT-1 deficiency, 
4) acute cardio-vascular incident, and 5) pregnancy.
Patients were treated and discharged accor-
ding to current GOLD guidelines with the use 
of bronchodilatators, oxygen, systemic steroids, 
antibiotics, and deep vein thrombosis prophyla-
xis [4]. Seven (17.5%) of the most severe COPD 
patients were treated with noninvasive positive 
pressure ventilation (NIV), and patients with ob-
structive sleep apnoea (OSA) were treated with 
CPAP. Coexisting diseases were treated according 
to previous treatment plans and adequate guideli-
nes. Sixteen patients with the most severe COPD 
stage were already on and were maintained on 
home oxygen treatment after hospitalisation. 
Study design
The study was designed and performed as 
a prospective cohort study with no control group. 
All tests were performed between 7.00 AM and 
1.00 PM during the first day and repeated during 
the last day of hospitalisation. After collecting 
fasting blood samples, patients took part in re-
spiratory functional tests. Subsequently, 6MWT 
was performed. Transthoracic echocardiography 
(TTE) was performed within one day from ad-
mission and repeated ± one day from discharge. 
Pulmonary function testing
Pulmonary function tests were performed 
with the use of diagnostic system MasterLab Jeager 
(Wuerzburg, Germany) including spirometry (to 
confirm COPD diagnosis and to asses disease se-
verity) [4, 17]), body plethysmography (to measure 
hyperinflation) indices [18]), and DLCO [19], but 
thoracic gas volumes obtained at diffusion me-
asurement were not included in the final results 
because of the high possibility of gas misdistribu-
tion in patients with severe COPD exacerbation. 
Transthoracic echocardiography
Patients were screened for PHT with the use 
of TTE, according to current ERS/ESC recommen-
dations [10], by one cardiologist blinded to all 
other patient data. Results considered indicative 
for pulmonary hypertension were RVSP > 35 mm 
Hg [20], and PAPmean ≥ 25 mm Hg. Standard TTE 
was performed using Toshiba APILO, (Japan) and 
transducer PST-30BT with continuous Doppler 
with frequency of 3 MHz. 
Pulmonary artery systolic pressure (PASP) was 
indirectly calculated according to the equation:
PASP = 4v2 + RAP
PASP — systolic pressure in right ventricle 
(RVSP) in the absence of pulmonary artery ste-
nosis.
v — maximal velocity of tricuspid regurgi-
tation jet
RAP — Right atrial pressure: estimated from 
the diameter and inspiratory collapse of the in-
ferior vena cava [21].
Additionally, PAPmean was calculated with 
the use of the Mahama equation because the tricu-
spid regurgitation jet is often difficult to visualise 
in COPD patients.
PAPmean = 79 — (0.45 . Act)
AcT — pulmonary artery valve flow accele-
ration time
PAPmean — mean pulmonary arterial pressu-
re calculated with a use of the Mahama equation
TAPSE — tricuspid annular plane systolic 
excursion was assessed by a cardiologist blinded 
to other treatment results. 
Exercise capacity and dyspnoea 
Six-minute walk test (6MWT) with conti-
nuous oxygen saturation monitoring was perfor-
med to assess physical capacity [22]. 6MWT was 
performed without oxygen supplementation. To 
assess dyspnoea, the MRC scale was used [23].
Blood tests
Basic blood tests required for in-ward COPD 
exacerbation treatment were performed in the 
certified laboratory. Serum samples for ET-1 and 
NT-proBNP measurement were frozen at –78oC, 
immediately after being collected and subsequ-
ently measured by ELISA kits (Biomedica Gmgh) 
according to the manufacturer`s protocol in all 
patients. 
Statistical analysis
Statistical evaluation was performed using 
software package Statistica 6.0 (StatSoft Inc, 
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Table 1. Characteristics of the included patients 
Value Unit
Number of participants included 40 [n]
GOLD I٭ 1; 2.5 [n]; (%)
GOLD II٭ 12; 30 [n]; (%)
GOLD III٭ 11; 27.5 [n]; (%)
GOLD IV٭ 16; 40 [n]; (%)
Presence of hyperinflation٭٭ 24; 60 [n]; (%)
Age 67 ± 8; (45–80) [years]
Sex (M/F) 4/36; 10/90 [n]; (%)
Smoking history*** 43; (20–100) [pack-years]
Hospitalization time*** 13; (4–40) [days]
BMI 27.8 ± 5.7; (17.3–39.8) [kg/m2]
٭GOLD guidelines — at discharge 
٭٭Static hyperinflation on admission: ITGV > 140%N, and RV%TLC > 140%N 
***Medians and ranges
Table 2. Spirometry results 





1.7 1.6 0.8 2.8 0.5
p = 0.4
Post-IC [L] 1.8 1.8 0.4 3.6 0.7
Pre-VC IN [L]
40
2.3 2.2 1.1 3.5 0.6
p = 0.002
Post-VC IN[L] 2.6 2.5 1.0 4.6 0.7
Pre-FEV1 [L]
40
1.0 1.1 0.5 2.0 0.4
p < 0.001
Post-FEV1 [L] 1.2 1.1 0.2 3.1 0.5
Pre-FVC [L]
40
2.1 2.0 0.7 3.2 0.6
p = 0.001
Post-FVC [L] 2.4 2.4 0.6 4.8 0.7
Pre-FEV1%FVC (%)
40
50.3 49.4 26.9 75.8 11.3
p = 0.3
Post-FEV1%FVC (%) 51.2 50.3 31.8 95.1 12.4
Statistically significant differences (p < 0.05) and ↓ or ↑ points direction of changes
Tulsa, Oklahoma). Kolmogorov-Smirnov test was 
used to test variables for normal distribution. 
Student’s t-test and Wilcoxon test were used to 
determine pre-post differences. Spearman rank 
correlation test was used to evaluate correlations 
between variables. P < 0.05 was accepted as sta-
tistically significant.
Results
Forty patients with a mean age of 67 ± 8 years 
represented by 90% males with COPD exacerba-
tion were studied. Hyperinflation [intra thoracic 
gas volume (ITGV) > 140%N and residual volu-
me percentage total lung capacity (RV%TLC) > 
140%N] was present in 60% of the 40 subjects 
included in the study. Most of the patients were 
GOLD stage III and IV [4]. Patient’s characteristics 
are summarised in Table 1. 
Pulmonary function tests
The results of spirometry and plethysmo-
graphy are presented in detail in Tables 2 and 
3. Effective exacerbation treatment resulted in 
airway patency improvement (FEV1-improve-
ment) (Table 2). Significant changes were noticed 
in most spirometric variables studied but not 
in IC. A significant reduction of post-treatment 
RV%TLC value was noticed (Table 3). A signi-
ficant increase in diffusion capacity calculated 
for alveolar volume (DLCO/VA) [mmol/min/
kPa/l] was noticed in the subgroup of primarily 
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Table 3. Body plethysmography and DLCO results 





0.8 0.7 0.3 2.2 0.4
p = 0.5
Post-Rtot[kPa × s/l] 0.8 0.6 0.2 3.9 0.6
Pre-ITGV [L]
38
5.3 5.2 2.6 11.0 1.4
p = 0.5
Post-ITGV [L] 5.2 5.1 2.4 7.8 1.3
Pre-RV%TLC (%)
38
64.3 63.4 44.5 81.9 9.0
p = 0.03
Post-RV%TLC(%) 60.6 64.0 27.8 81.5 11.1
Pre-TLC [L]
38
6.9 6.9 4.6 11.9 1.4
p = 0.66
Post- TLC [L] 7.0 7.0 2.9 10.0 1.5
Pre-RV [L]
38
4.5 4.5 2.4 9.8 1.3
p = 0.37
Post- RV [L] 4.3 4.4 1.1 7.2 1.4
Pre-DLCO/VA [mmol/min/kPa/L]
38
1.1 1.1 0.4 2.4 0.5
p = 0.24
Post-DLCO/VA [mmol/min/kPa/L] 1.2 1.2 0.5 2.4 0.5
Statistically significant differences (p < 0.05) and ↓ or ↑ points direction of changes
Table 4. Transthoracic echocardiography results 





28.6 28.0 21.0 38.0 5.0
p = 0.03
Post-Right ventricle [mm] 26.9 25.1 21.0 37.0 4.0
Pre-RV FAC% (%)
11
55.3 57.0 27.0 72.0 13.3
p = 0.06
Post-RV FAC% (%) 56.2 55.0 41.0 79.0 10.5
Pre-RV/LV ratio in 4C
11
0.8 0.7 0.5 1.3 0.3
p = 0.3
Post-RV/LV ratio in 4C 0.8 0.7 0.6 1.1 0.1
Pre-TAPSE [mm]
6
15.2 17.0 8.0 21.8 4.6
p = 0.07
Post-TAPSE [mm] 17.5 17.8 10.4 24.6 3.7
Pre-RVSP [mm Hg]
4
44.5 46.0 26.0 63.5 12.9
p = 0.07
Post-RVSP [mm Hg] 36.3 39.0 9.8 58.5 14.3
Pre-VCI diameter [mm]
10
20.7 19.9 14.8 28.0 3.9
p = 0.08
Post-VCI diameter [mm] 20.0 21.1 11.0 26.6 4.7
Pre-PAP mean (Mahama) [mm Hg]
11
41.2 40.1 22.0 61.0 11.2
p = 0.03
Post-PAP mean (Mahama) [mm Hg] 40.1 43.0 16.0 61.0 13.0
Pre-LVEF% (%)
10
53.2 55.0 29.0 63.0 9.9
p = 0.7
Post-LVEF% (%) 54.9 58.0 27.0 66.0 10.2
Statistically significant differences (p < 0.05) and ↓ or ↑ points direction of changes
hyperinflated COPD subjects only: (pre-treat-
ment: 0.95 ± 0.35; post-treatment: 1.02 ± 0.36; 
p = 0.014), but not in the entire group (pre-treatment: 
1.13 ± 0.47; post-treatment: 1.18 ± 0.46; p = 0.2). 
Transthoracic echocardiography
We aimed to perform TTE in all patients, but 
reliable results as predicted [24] could have been 
obtained pre and post treatment only in about 
25% of cases, depending largely on the patient’s 
clinical condition and decreased echocardio-
graphic window caused by emphysema. The 
results of TTE are presented in Table 4. Success-
ful treatment was associated with a significant 
decrease of PAPmean. The trend of decreased 
RVSP and increased tricuspid annular plane sys-
Szymon Skoczyński et al., Lung-heart clinical crosstalk in the course of COPD exacerbation
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Table 5. Exercise capacity and dyspnoea indices 





294 310 10 550 132.1
p < 0.001
Post-6MWT [m] 415 440 120 610 102.1
Pre-treatment-SaO2min-6MWT (%) 
38
83 86 48 96 10.8
p = 0.001
Post-treatment-SaO2min-6MWT (%) 87 89 67 96 7.5
Pre-MRC [points]
40
3.3 3.5 2.0 4.0 0.8
p < 0.001
Post-MRC [points] 1.8 2.0 0.0 4.0 0.9
Statistically significant differences (p < 0.05) and ↓ or ↑ points direction of changes
tolic excursion (TAPSE) was noticed (Table 4), but 
post-treatment values of both indices were still 
outside the normal range (Table 4). No changes in 
left ventricle ejection fraction were observed. Post
-treatment RVSP values were higher (p < 0.05) in 
the subgroup of COPD patients with concomitant 
obstructive sleep apnoea syndrome.
Exercise capacity and breathlessness
The results of 6MWT and dyspnoea scales are 
presented in Table 5. Significant improvement of 
exercise capacity (6MWT) and clinical symptoms 
(MRC scale) were noticed post-treatment. Not 
only distance, but also minimal saturation during 
6MWT was significantly higher after treatment, 
compared with baseline (Table 5).
Blood tests
There was a trend for reduction of ET-1 
concentrations [fmol/ml] in the course of treat-
ment: (pre-treatment: 1.7 ± 2.8; post-treatment: 
1.3 ± 1.9; p = 0.076; n = 38), but no changes 
in NT-proBNP levels [fmol/ml] were noticed: 
(pre-treatment: 17.5 ± 38.9; post-treatment: 
12.8 ± 18.6; p = 0.3; n = 38). Mean NT-proBNP 
concentration was in the lower range of normal 
values (normal value = 0-640 fmol/mL). There 
were no differences in resting oxygenation based 
on arterialised capillary blood gases SaO2 (%): 
pre-SaO2: 88.7 ± 8.5, post-SaO2: 91 ± 5.4; p = 0.1, 
PO2 [mm Hg]: pre-PO2: 58.5 ± 13.5; post-PO2: 62 ± 
11; p = 0.2. Except for a significant reduction in 
CRP concentrations [mg/L]: (pre-treatment: 29.6 
± 38.1; post-treatment: 9.0 ± 12.9; p = 0.004), 
no significant changes in other routinely assessed 
blood parameters were noticed. 
Correlations
Significant correlations between spirometric 
(IC) and plethysmographic (RV%TLC) markers of 
hyperinflation, and both, dyspnoea and exercise 
capacity were observed. 6MWT and MRC scales 
correlated with IC on admission (p < 0.05; r = 0.51; 
r = –0.53, respectively) as well as on discharge 
(p < 0.05; r = 0.55; r = –0.57, respectively). Also 
6MWT and MRC scales correlated with RV%TLC 
both, on admission: (p < 0.05; r = –0.46; r = 0.41, 
respectively) and on discharge: (p < 0.05; r = 
–0.53; r = 0.51, respectively).
IC correlated with FEV1 both, on admission, 
and on discharge (p < 0.05; r = 0.6; r = 0.72, 
respectively). Also RV%TLC correlated with FEV1 
on admission and on discharge (p < 0.05; r = 
–0.74; r = –0.69, respectively). FEV1 correlated 
with 6MWT on admission and discharge (p < 
0.05; r = 0.55; r = 0.60, respectively).
No correlations between PHT indices (RVSP, 
PAP-mean, ET-1, NT-proBNP) and 6MWT distance 
or MRC scale were noticed. 
Discussion
According to the authors’ best knowledge, 
this is the second study, after the report of Blan-
kenburg et al. [25], in which changes of exercise 
capacity (6MWT) were assessed at the beginning 
and at the resolution of severe COPD exacerba-
tion. However, only in our study were these pa-
rameters additionally referred to hyperinflation 
and PAP. 6MWT turned out to be a safe tool in 
evaluating the severity of COPD exacerbation, 
often more informative and easier to perform than 
pulmonary functional tests [17–19] or TTE [24]. 
The above-presented increase of post-treatment 
exercise capacity and simultaneous decrease of 
dyspnoea may both be explained by the reduced 
dynamic and static lung hyperinflation, as well 
as reduced bronchial obstruction. Although, ac-
cording to GOLD guidelines, there is no need to 
perform lung function tests on discharge [4], the 
authors found it clinically useful to perform at 
least spirometry. This is supported by observed 
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major FEV1 increase and its positive correlation 
with 6MWT distance and negative correlation 
with MRC score. The findings are in agreement 
with Stevenson et al. [26], indicating that the re-
solution of COPD exacerbation is related to incre-
ased values of operating lung volumes (FEV1, IC). 
Moreover, in our study we found that a relatively 
small, but significant improvement in RV%TLC 
(–4%) and FEV1 (+200 mL) may be accompanied 
by major (+121 m) improvement in 6MWT result, 
which is much higher than generally accepted as 
clinically significant [27, 28]. Another possible 
explanation for positive correlation of FEV1 and 
exercise is the fact that significant improvement 
of FEV1 is usually not observed in stable COPD. 
The minimal oxygen saturation during 6MWT in 
our study was significantly higher after treatment, 
when compared with baseline values. These data 
are of importance as they indicate that increased 
exercise tolerance was due to respiratory improve-
ment and not due to the doctor forcing the patient 
to march faster or due to the patient’s learning 
potential [28]. As expected, IC has not revealed 
the degree of hyperinflation, whereas RV%TLC, 
as one of the most accurate methods of measuring 
hyperinflation, could reflect static hyperinflation 
changes [27, 29]. That is why, in contrast to what 
was previously established [30], in the authors’ 
opinion, COPD exacerbation itself is not enough 
to induce dynamic lung hyperinflation. The 
results of the study suggest that during the first 
phase of COPD exacerbation (hospital treatment) 
the reduction of dyspnoea at rest is probably 
caused by a decrease in lung volume (RV% TLC) 
and increase in bronchial patency (FEV1). The re-
sults obtained in our study indirectly suggest that 
small changes in static hyperinflation (RV%TLC) 
are probably followed by much more significant 
changes in lung volumes that accompany physical 
exertion and are responsible for better post-treat-
ment exercise tolerance. 
In our study we decided not to conduct pul-
monary function tests directly after 6MWT becau-
se most of the patients had severe post-exercise 
dyspnoea. We therefore assumed that obtaining 
reliable pulmonary post-exercise function test 
results in those patients would be impossible 
[17–19]. 
Data on pulmonary haemodynamics in the 
course of COPD exacerbation are sparse. Although 
we lack direct proof, on the basis of our results we 
can speculate that effective COPD exacerbation 
treatment and symptom relieve is associated with 
reduced risk of developing dynamic hyperinfla-
tion on exercise and, in turn, less pronounced 
compression of pulmonary capillaries by hyperin-
flated lungs [31]. According to our best knowled-
ge, this is the first study that shows that standard 
COPD exacerbation treatment [4] decreases mPAP. 
There were no differences in resting oxygenation 
based on arterialised capillary blood gases. The 
observed post-treatment PAPmean and RVSP re-
duction were independent of dyspnoea, exercise 
capacity, and blood gasses, which might be the re-
sult of oxygen supplementation [32]. In the study 
by Weitzenblum et al. [33] changes of right heart 
haemodynamics were observed during an episode 
of peripheral oedema. However, an episode like 
this could also have been related to right ventricle 
decompensation, independent of COPD exacerba-
tion. According to the authors’ best knowledge, 
this is also the first study in which 6MWT and 
pulmonary hyperinflation were analysed in re-
lation to TTE and laboratory biomarkers of right 
and left heart function in the course of COPD exa-
cerbation treatment. The analysis of correlations 
between cardiac and pulmonary parameters was 
conducted because of high coincidence of COPD 
and cardio-vascular diseases [3, 4, 34]. As expec-
ted, the number of patients reliably examined by 
TTE was much smaller than those who were able 
to perform pulmonary function tests (Tables 2–4) 
[24]. This might partially explain why the si-
gnificant reduction of PAPmean was accompa-
nied only by a trend for reduced RVSP. Accor-
ding to pulmonary hypertension guidelines [10] 
and as suspected, moderately increased PAP on 
admission was found and then was partially re-
duced by the exacerbation treatment [4] (Table 4). 
Similarly to Hanaoka et al. [33], but engaging 
a larger number of patients, we showed that PAP 
increases during COPD exacerbation. The results 
of both studies raise the unresolved question of 
whether there is a need for a larger study with 
pulmonary artery pressure PAP assessed by right 
heart catheterisation (RHC). On the basis of our 
study, it is impossible to determine the exact 
role of different mechanisms causing PHT in 
the course of COPD exacerbation. Similarly to 
Bacakoğlu et al. [14], the authors have observed 
that ET-1 concentration decreases in the course of 
COPD exacerbation treatment, but no correlation 
between its levels and PHT values were found. 
This might be explained by ET-1 probably being 
secreted and metabolised mainly in the pulmona-
ry vascular bed wall [35]. Left heart insufficiency, 
one of the major causes of secondary PHT [10], 
was not a reason for PHT in our study (Table 4) 
as the LVEF was within normal range in most 
patients in the studied group [12]. The results 
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are not in agreement with Stolz et al. [36], who 
revealed that BNP levels are elevated during 
COPD exacerbation. This discrepancy might be 
explained by the fact that in the study by Stolz et 
al. [37] blood was collected directly on admission 
and again at follow-up after hospitalisation. Also, 
in the study by Stolz et al. [37] most patients 
were not assessed with TTE on admission, which 
makes the coincidence of right and/or left heart 
decompensation on BNP levels quite possible. 
The main limitation of the study is the rela-
tively small number of patients with TTE assess-
ment, which results from a weak acoustic window 
typical for patients with COPD. The authors are 
fully aware that TTE assessment of PAP is only 
a screening tool. However, it was more ethical to 
perform TTE than RHC, especially when taking 
into account that there are no recommendations 
for PHT-specific treatment in patients with COPD 
exacerbation [10]. 
Conclusions
The results of our study suggest that COPD 
exacerbation induces static lung hyperinflation in 
about two-thirds of patients. Pulmonary hyperin-
flation and bronchial obstruction may be reduced 
by standard GOLD-COPD exacerbation treatment 
and are associated with improvement of exercise 
tolerance and dyspnoea reduction.
COPD exacerbation and its treatment chan-
ge right, but not left, ventricle haemodynamics. 
Pulmonary artery pressure reduction is probably 
independent of clinical improvement. 6MWT 
may be a useful test in the assessment of patients 
treated for COPD exacerbation.
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